1
|
Monteagudo B, Marqués FM, Gibelin J, Orr NA, Corsi A, Kubota Y, Casal J, Gómez-Camacho J, Authelet G, Baba H, Caesar C, Calvet D, Delbart A, Dozono M, Feng J, Flavigny F, Gheller JM, Giganon A, Gillibert A, Hasegawa K, Isobe T, Kanaya Y, Kawakami S, Kim D, Kiyokawa Y, Kobayashi M, Kobayashi N, Kobayashi T, Kondo Y, Korkulu Z, Koyama S, Lapoux V, Maeda Y, Motobayashi T, Miyazaki T, Nakamura T, Nakatsuka N, Nishio Y, Obertelli A, Ohkura A, Ota S, Otsu H, Ozaki T, Panin V, Paschalis S, Pollacco EC, Reichert S, Rousse JY, Saito AT, Sakaguchi S, Sako M, Santamaria C, Sasano M, Sato H, Shikata M, Shimizu Y, Shindo Y, Stuhl L, Sumikama T, Sun YL, Tabata M, Togano Y, Tsubota J, Uesaka T, Yang ZH, Yasuda J, Yoneda K, Zenihiro J. Mass, Spectroscopy, and Two-Neutron Decay of ^{16}Be. Phys Rev Lett 2024; 132:082501. [PMID: 38457706 DOI: 10.1103/physrevlett.132.082501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 12/18/2023] [Accepted: 01/29/2024] [Indexed: 03/10/2024]
Abstract
The structure and decay of the most neutron-rich beryllium isotope, ^{16}Be, has been investigated following proton knockout from a high-energy ^{17}B beam. Two relatively narrow resonances were observed for the first time, with energies of 0.84(3) and 2.15(5) MeV above the two-neutron decay threshold and widths of 0.32(8) and 0.95(15) MeV, respectively. These were assigned to be the ground (J^{π}=0^{+}) and first excited (2^{+}) state, with E_{x}=1.31(6) MeV. The mass excess of ^{16}Be was thus deduced to be 56.93(13) MeV, some 0.5 MeV more bound than the only previous measurement. Both states were observed to decay by direct two-neutron emission. Calculations incorporating the evolution of the wave function during the decay as a genuine three-body process reproduced the principal characteristics of the neutron-neutron energy spectra for both levels, indicating that the ground state exhibits a strong spatially compact dineutron component, while the 2^{+} level presents a far more diffuse neutron-neutron distribution.
Collapse
Affiliation(s)
- B Monteagudo
- LPC Caen, ENSICAEN, CNRS/IN2P3, Université de Caen, Normandie Université, 14050 Caen, France
- FRIB, Michigan State University, East Lansing, Michigan 48824, USA
| | - F M Marqués
- LPC Caen, ENSICAEN, CNRS/IN2P3, Université de Caen, Normandie Université, 14050 Caen, France
| | - J Gibelin
- LPC Caen, ENSICAEN, CNRS/IN2P3, Université de Caen, Normandie Université, 14050 Caen, France
| | - N A Orr
- LPC Caen, ENSICAEN, CNRS/IN2P3, Université de Caen, Normandie Université, 14050 Caen, France
| | - A Corsi
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - Y Kubota
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
- Department of Physics, Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - J Casal
- Dipartimento di Fisica e Astronomia "G. Galilei" and INFN-Sezione di Padova, Via Marzolo 8, 35131 Padova, Italy
- Departamento de Física Atómica, Molecular y Nuclear, Facultad de Física, Universidad de Sevilla, Apartado 1065, E-41080 Sevilla, Spain
| | - J Gómez-Camacho
- Departamento de Física Atómica, Molecular y Nuclear, Facultad de Física, Universidad de Sevilla, Apartado 1065, E-41080 Sevilla, Spain
| | - G Authelet
- Département des Accélérateurs, de Cryogénie et de Magnétisme, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - H Baba
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - C Caesar
- Department of Physics, Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - D Calvet
- Département d'électronique des Détecteurs et d'Informatique pour la Physique, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A Delbart
- Département d'électronique des Détecteurs et d'Informatique pour la Physique, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - M Dozono
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - J Feng
- School of Physics, Peking University, Beijing 100871, China
| | - F Flavigny
- Institut de Physique Nucléaire, IN2P3-CNRS, Université Paris-Sud, Université Paris-Saclay, 91406 Orsay Cedex, France
| | - J-M Gheller
- Département des Accélérateurs, de Cryogénie et de Magnétisme, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A Giganon
- Département d'électronique des Détecteurs et d'Informatique pour la Physique, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A Gillibert
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - K Hasegawa
- Department of Physics, Tohoku University, Miyagi 980-8578, Japan
| | - T Isobe
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Kanaya
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - S Kawakami
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - D Kim
- Department of Physics, Ewha Womans University, Republic of Korea
| | - Y Kiyokawa
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - M Kobayashi
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - N Kobayashi
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - T Kobayashi
- Department of Physics, Tohoku University, Miyagi 980-8578, Japan
| | - Y Kondo
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - Z Korkulu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - S Koyama
- Department of Physics, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - V Lapoux
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - Y Maeda
- Department of Applied Physics, University of Miyazaki, Gakuen-Kibanadai-Nishi 1-1, Miyazaki 889-2192, Japan
| | - T Motobayashi
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Miyazaki
- Department of Physics, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - T Nakamura
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - N Nakatsuka
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - Y Nishio
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - A Obertelli
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Department of Physics, Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - A Ohkura
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - S Ota
- Center for Nuclear Study, University of Tokyo, Hongo 7-3-1, Bunkyo, Tokyo 113-0033, Japan
| | - H Otsu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Ozaki
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - V Panin
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - S Paschalis
- Department of Physics, Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - E C Pollacco
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - S Reichert
- Department of Physics, Technische Universität Munchen, 85748 Garching bei München, Germany
| | - J-Y Rousse
- Département d'Ingénierie des Systèmes, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A T Saito
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - S Sakaguchi
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - M Sako
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - C Santamaria
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - M Sasano
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - H Sato
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - M Shikata
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - Y Shimizu
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Shindo
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - L Stuhl
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Sumikama
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y L Sun
- Département de Physique Nucléaire, IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Department of Physics, Institut für Kernphysik, Technische Universität Darmstadt, D-64289 Darmstadt, Germany
| | - M Tabata
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - Y Togano
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - J Tsubota
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - T Uesaka
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Z H Yang
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - J Yasuda
- Department of Physics, Kyushu University, Nishi, Fukuoka 819-0367, Japan
| | - K Yoneda
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - J Zenihiro
- RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| |
Collapse
|
2
|
Benatar IF, Sa A, Sole E, Castel M, Caravaca P, Alvarez AG, Sandoval E, Marquez NI, Canto P, Rodriguez J, Cepas P, Sabate M, Casal J, Izquierdo L, Torrecilla E, Torres MF. Super Accelerated Cardiac Allograft Vasculopathy. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
3
|
Ibarra Marquez N, Sole E, Castel M, Broseta J, Sandoval E, Caravaca P, Sa A, Cordoba P, Forado I, Rodriguez J, Casal J, Torrecilla E, Izquierdo L, Simon C, Quintana E, Farrero Torres M. Heartmate 3 and Home Hemodialysis as a Bridge to Heart-Kidney Transplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
4
|
Benavides B, Casal J, Diéguez J, Yus E, Moya SJ, Allepuz A. Quantitative risk assessment of introduction of BVDV and BoHV-1 through indirect contacts based on implemented biosecurity measures in dairy farms of Spain. Prev Vet Med 2021; 188:105263. [PMID: 33453562 DOI: 10.1016/j.prevetmed.2021.105263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 12/29/2020] [Accepted: 01/05/2021] [Indexed: 11/18/2022]
Abstract
A stochastic quantitative risk assessment model was developed to estimate the annual probability of introduction of bovine viral diarrhea virus (BVDV) and bovine herpesvirus 1 (BoHV-1) on 127 dairy farms through indirect contacts. Vehicles transporting calves, cattle to slaughterhouse, dead animals, and mixture of feed, as well as visits by veterinarians and hoof trimmers, farm workers and contacts with neighbors were considered in the model. Data from biosecurity questionnaires of each farm, scientific literature and expert opinion from field veterinarians, animal vehicle drivers, hoof trimmers and personnel from rendering transport companies were used to estimate values for input parameters. Results showed that the annual probability of introducing BVDV or BoHV-1 through indirect contacts was very heterogeneous. The overall distribution of median values for each farm ranged from 0.5 to 14.6% and from 1.0 to 24.9% for BVDV and BoHV-1, respectively. The model identified that providing protective clothing and boots to visits, not allowing the animal vehicle driver to come into contact with animals present on the farm and ensuring that calf vehicles arrived empty, were the measures with the highest impact on the probability of infection for most farms. This model could be a useful tool to show the impact of the measures to farmers and veterinarians, thus increasing their awareness on biosecurity. In addition, it could support decision making on which measures should be prioritized in dairy cattle herds to reduce the probability of introduction of diseases.
Collapse
Affiliation(s)
- B Benavides
- Department de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Department of Animal Health, Universidad de Nariño, Pasto, Colombia
| | - J Casal
- Department de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Centre de Recerca en Sanitat Animal (CReSA), Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Spain
| | - J Diéguez
- Department of Anatomy and Animal Production, Universidad de Santiago de Compostela (USC), Lugo, Spain
| | - E Yus
- Department of Animal Pathology, Universidad de Santiago de Compostela (USC), Lugo, Spain
| | - S J Moya
- Department de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - A Allepuz
- Department de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Centre de Recerca en Sanitat Animal (CReSA), Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Spain.
| |
Collapse
|
5
|
Villamil FJ, Yus E, Benavides B, Casal J, Moya SJ, Allepuz A, Diéguez FJ. Short communication: Risk factors associated with Mycobacterium avium ssp. paratuberculosis introduction into dairy herds in Galicia, northwestern Spain. J Dairy Sci 2020; 103:7411-7415. [PMID: 32534928 DOI: 10.3168/jds.2020-18210] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Accepted: 04/13/2020] [Indexed: 12/16/2022]
Abstract
This study assessed potential risk factors associated with introduction of Mycobacterium avium ssp. paratuberculosis (MAP) into dairy cattle herds in the Galicia region, northwestern Spain. The study was carried out with data collected from 93 dairies enrolled in a voluntary MAP control program. Information on potential risk factors was obtained through personal interviews with the farmers and veterinarians in charge of the control program of each farm. In addition, blood samples were taken annually over 2 years from cows on the farms in the program, and analyzed with a commercial ELISA to detect antibodies to MAP. Fecal samples of all ELISA-positive cows were analyzed using PCR. Based on χ2 test and Fisher's exact test, purchase practices, shared manure truck, shared materials, and visitors per month who contacted animals were found to be significantly associated with farm MAP infection status. Multiple logistic regression indicated that purchase practices and herd size (included as a potential confounder) are the variables that best predict MAP status.
Collapse
Affiliation(s)
- F J Villamil
- Agrupación de Defensa Sanitaria (ADSG), Costa da Morte, 15153, A Coruña, Galicia, Spain
| | - E Yus
- Institute of Food Analysis and Research (Animal Health and Epidemiology Unit), Veterinary Faculty of Lugo, Santiago de Compostela University, 27002, Lugo, Spain
| | - B Benavides
- Grupo de investigación de Buiatria, Programa Medicina Veterinaria, Facultad de Ciencias Pecuarias, Universidad de Nariño, 522020, Pasto, Colombia
| | - J Casal
- Department of Health and Anatomy Animal, Universitat Autònoma de Barcelona (UAB), 08193, Barcelona, Spain; Centre de Recerca en Sanitat Animal (CReSA)-Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Barcelona, 08193, Spain
| | - S J Moya
- Department of Health and Anatomy Animal, Universitat Autònoma de Barcelona (UAB), 08193, Barcelona, Spain
| | - A Allepuz
- Department of Health and Anatomy Animal, Universitat Autònoma de Barcelona (UAB), 08193, Barcelona, Spain; Centre de Recerca en Sanitat Animal (CReSA)-Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Barcelona, 08193, Spain
| | - F J Diéguez
- Anatomy and Animal Production, and Clinical Veterinary Sciences Department, Veterinary Faculty of Lugo, Santiago de Compostela University, Campus Universitario, 27002 Lugo, Spain.
| |
Collapse
|
6
|
Benavides B, Casal J, Diéguez JF, Yus E, Moya SJ, Armengol R, Allepuz A. Development of a quantitative risk assessment of bovine viral diarrhea virus and bovine herpesvirus-1 introduction in dairy cattle herds to improve biosecurity. J Dairy Sci 2020; 103:6454-6472. [PMID: 32359990 DOI: 10.3168/jds.2019-17827] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Accepted: 02/29/2020] [Indexed: 01/16/2023]
Abstract
A quantitative risk assessment model was developed to estimate the annual probability of introducing bovine viral diarrhea virus (BVDV) and bovine herpesvirus 1 (BoHV-1) at the farm level through animal movements. Data from 2017 official animal movements, biosecurity questionnaires, scientific literature, and expert opinion from field veterinarians were taken into consideration for model input parameters. Purchasing or introducing cattle, rearing replacement heifers offsite, showing cattle at competitions, sharing transport vehicles with other herds, and transporting cattle in vehicles that have not been cleaned and disinfected were considered in the model. The annual probability of introducing BVDV or BoHV-1 through infected animals was very heterogeneous between farms. The median likelihoods of BVDV and BoHV-1introduction were 12 and 9%, respectively. Farms that purchased cattle from within their region (i.e., local movements) and shared transport with other farms had a higher probability for BVDV and BoHV-1 introduction. This model can be a useful tool to support decision-making on biosecurity measures that should be prioritized to reduce the probability of introduction of these 2 diseases in dairy herds.
Collapse
Affiliation(s)
- B Benavides
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, Cerdanyola del Vallès, 08193, Spain; Department of Animal Health, Universidad de Nariño, Pasto, 520002, Colombia.
| | - J Casal
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, Cerdanyola del Vallès, 08193, Spain; Centre de Recerca en Sanitat Animal (CReSA), Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Cerdanyola del Vallès, 08193, Spain
| | - J F Diéguez
- Department of Anatomy and Animal Production, Universidad de Santiago de Compostela, Lugo, 15703, Spain
| | - E Yus
- Department of Animal Pathology, Universidad de Santiago de Compostela, Lugo, 15703, Spain
| | - S J Moya
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, Cerdanyola del Vallès, 08193, Spain
| | - R Armengol
- Department of Animal Science, Universitat de Lleida, Lleida, 25002, Spain
| | - A Allepuz
- Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, Cerdanyola del Vallès, 08193, Spain; Centre de Recerca en Sanitat Animal (CReSA), Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Cerdanyola del Vallès, 08193, Spain.
| |
Collapse
|
7
|
Domínguez JM, Keller B, Moisés J, Spitaleri G, Farrero M, Casal J, Pérez-Villa F, Castel MA. Changes in Pulmonary Function in Patients With Advanced Heart Failure Listed for Heart Transplantation. Transplant Proc 2019; 51:3424-3427. [PMID: 31810509 DOI: 10.1016/j.transproceed.2019.09.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 09/09/2019] [Accepted: 09/21/2019] [Indexed: 12/28/2022]
Abstract
BACKGROUND Pulmonary function tests (PFTs) are often impaired in patients with advanced heart failure. There is limited data about their impact on survival after heart transplantation (HT). We sought to assess the prevalence and type of PFT abnormalities in patients on HT waiting list and their impact on outcomes. METHODS We performed a retrospective analysis of a prospective registry of consecutive patients undergoing HT between 2012 and 2018. Patients were classified into 4 groups according to pre-HT PFT results: 1. normal pattern: forced vital capacity (FVC) ≥ 80% and forced expiratory volume in 1 second (FEV1) to FVC ratio (FEV1/FVC) ≥ 0.7; 2. obstructive: FEV1/FVC < 0.7; 3. nonobstructive: FEV1/FVC ≥ 0.7 and FVC < 80% when total lung capacity value was not available; and 4. restrictive: FEV1/FVC ≥ 0.7 and total lung capacity < 80%. The prevalence of impaired carbon monoxide diffusing capacity corrected for hemoglobin < 80% and FEV1 < 70% was also analyzed. High-urgency HT patients and those referred from other centers without quantitative pulmonary evaluation were excluded. RESULTS Among 123 patients who underwent HT, 83 patients with complete PFT were included. Median follow-up was 2.7 ± 1.9 years. Of these, 29 (34.9%) had an obstructive pattern, 20 (24.1%) a nonobstructive, 18 (21.7%) a restrictive, and 16 (19.3%) a normal pattern. Fifty-one (61.4%) patients had FEV1 < 70% and 58 (69.9%) a carbon monoxide diffusing capacity corrected for hemoglobin < 80%. There was a tendency to lower survival in all altered PFT groups compared with normal (P = .054) but not within the other groups. Patients with an impaired FEV1 had significantly higher mortality than patients with normal values (P = .008). Area under receiver operating characteristic curve for FEV1 was 0.73 (95% confidence interval [0.60-0.86]). A cutoff value of FEV1 (60.5) predicts mortality with 66% sensitivity and 64% specificity. CONCLUSIONS PFT alterations have a very high prevalence on HT waiting list patients. Patients with impaired FEV1 had worse outcomes after heart transplantation.
Collapse
Affiliation(s)
- J M Domínguez
- Cardiovascular Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
| | - B Keller
- Cardiovascular Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
| | - J Moisés
- Pneumology department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
| | - G Spitaleri
- Cardiovascular Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
| | - M Farrero
- Cardiovascular Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
| | - J Casal
- Cardiovascular Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
| | - F Pérez-Villa
- Cardiovascular Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
| | - M A Castel
- Cardiovascular Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
8
|
Provencio M, Nadal E, Insa A, Campelo RG, Casal J, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeno J, Cobo M, López-Vivanco G, Del Barco E, Bernabe R, Viñolas N, Barneto I, Viteri S, Martorell PM, Jove M, De Juan VC, Massuti B. OA13.05 NADIM Study: Updated Clinical Research and Outcomes. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.480] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Rodriguez Abreu D, Guirado M, Camps Herrero C, Bosch Barrera J, Bernabé R, Casal J, García-Campelo MR, Gonzalez-Larriba J, Massuti Sureda B, Ortega Granados A, Domine Gomez M, Sala M, Padilla A, Del Barco Morillo E, Oramas Rodriguez J, Blanco Guerrero R, Aguiar Bujanda D, López Castro R, Carcereny Costa E, Provencio M. Biomarker testing of lung cancer in Spain. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz266.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Casal J, Fortunato L, Vitturi A, Lanza E. Three-body description of 12C: From the hyperspherical formulation to the algebraic cluster model and its application to α + 12C inelasticscattering. EPJ Web Conf 2019. [DOI: 10.1051/epjconf/201922301008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Form factors for α+12C inelastic scattering are obtained within two theoretical (α+α+α) approaches:The hyperspherical framework for three identical bosons, and the algebraic cluster model assuming the D3h symmetry of an equilateral triangle subject to rotations and vibrations. Results show a good agreement, with form factors involving the Hoyle state having a slightly larger extension within the hyperspherical approach. Coupled-channel calculations using these form factors are ongoing.
Collapse
|
11
|
Ciaravino G, García-Saenz A, Cabras S, Allepuz A, Casal J, García-Bocanegra I, De Koeijer A, Gubbins S, Sáez JL, Cano-Terriza D, Napp S. Assessing the variability in transmission of bovine tuberculosis within Spanish cattle herds. Epidemics 2018; 23:110-120. [PMID: 29415865 DOI: 10.1016/j.epidem.2018.01.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 01/12/2018] [Accepted: 01/20/2018] [Indexed: 11/30/2022] Open
Abstract
In Spain, despite years of efforts to eradicate bovine tuberculosis (bTB), the disease is still endemic, with some areas of high prevalence. In this context, the surveillance and control plans may need to be re-evaluated, and understanding the dynamics of bTB spread within Spanish herds may help to develop new strategies for reducing the time for detection of infected herds and for the elimination of bTB from the herds already infected. Here, we developed a compartmental stochastic model to simulate bTB within-herd transmission, fed it with epidemiological data from 22 herds (obtained from a previous work) and carried out parameter inference using Approximate Bayesian Computing methods We also estimated the "Within-herd transmission potential Number" (Rh), i.e. the average number of secondary cases generated by a single animal infected introduced into a totally susceptible herd, considering different scenarios depending on the frequency of controls. The median global values obtained for the transmission parameters were: for the transmission coefficient (β), 0.014 newly infected animals per infectious individual per day (i.e. 5.2 per year), for the rate at which infected individuals become infectious (α), 0.01 per day (equivalent to a latent period of 97 days), and for the rate at which infected individuals become reactive to the skin test (α1), 0.08 per day (equivalent to a period of 12 days for an infected animal to become reactive). However, the results also evidenced a great variability in the estimates of those parameters (in particular β and α) among the 22 herds. Considering a 6-month interval between tests, the mean Rh was 0.23, increasing to 0.82 with an interval of 1 year, and to 2.01 and 3.47 with testing intervals of 2 and 4 years, respectively.
Collapse
Affiliation(s)
- G Ciaravino
- Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Barcelona, Spain.
| | - A García-Saenz
- Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Barcelona, Spain; ISGlobal (Barcelona Institute for Global Health - Epidemiology of Cancer), Campus MAR, Barcelona Biomedical Research Park (PRBB), 08003 Barcelona, Spain
| | - S Cabras
- Department of Statistics, Universidad Carlos III de Madrid, 28903 Getafe, Madrid, Spain; Department of Mathematics and Informatics, Università degli Studi di Cagliari, 09124 Cagliari, Italy
| | - A Allepuz
- Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Barcelona, Spain; Centre de Recerca en Sanitat Animal (CReSA) - Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
| | - J Casal
- Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Barcelona, Spain; Centre de Recerca en Sanitat Animal (CReSA) - Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
| | - I García-Bocanegra
- Departamento de Sanidad Animal, Facultad de Veterinaria, UCO, Campus Universitarios de Rabanales, 14014 Córdoba, Spain
| | - A De Koeijer
- Central Veterinary Institute (CVI), Wageningen UR, Lelystad, The Netherlands
| | - S Gubbins
- Institute for Animal Health, Pirbright Laboratory, Ash Road, Pirbright, Surrey GU24 0NF, UK
| | - J L Sáez
- Subdirección General de Sanidad e Higiene Animal y Trazabilidad, Dirección General de la Producción Agraria, Ministerio de Agricultura y Pesca, Alimentación y Medio Ambiente, Madrid, Spain
| | - D Cano-Terriza
- Departamento de Sanidad Animal, Facultad de Veterinaria, UCO, Campus Universitarios de Rabanales, 14014 Córdoba, Spain
| | - S Napp
- Centre de Recerca en Sanitat Animal (CReSA) - Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
| |
Collapse
|
12
|
Renault V, Humblet MF, Moons V, Bosquet G, Gauthier B, Cebrián LM, Casal J, Saegerman C. Rural veterinarian's perception and practices in terms of biosecurity across three European countries. Transbound Emerg Dis 2017; 65:e183-e193. [PMID: 28940807 DOI: 10.1111/tbed.12719] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Indexed: 11/29/2022]
Abstract
The implementation of biosecurity measures in the animal health and production context is quite broad and aims at limiting the risk of introduction and spread of diseases. Veterinarians play a major role in biosecurity as key informants on the subject for cattle holders, key players in terms of disease prevention/control and eradication programs, as well as key risk factor in terms of disease dissemination. Many biosecurity studies have highlighted professional visitors such as veterinary practitioners as representing a high-risk factor in terms of disease introduction in animal facilities but, to date, very few studies have focused on the implementation level of biosecurity measures by veterinarians. An online survey was implemented in three European countries (Belgium, France and Spain) to assess the behaviour of rural veterinarians towards biosecurity, as well as their implementation level of the biosecurity measures. A descriptive analysis of data and a scoring system were applied to assess the implementation level of measures. The influence of different factors on the implementation level of biosecurity measures was investigated through a negative binomial regression model. The study identified different strengths, weaknesses, possible constraints and solutions in terms of veterinary perspectives. Veterinarians are considered as key informants by the farmers and could therefore play a more active role in terms of guidance and improvement of biosecurity at farm level. Based on the survey outcomes, two factors seemed to influence significantly the implementation level of measures: the country where he/she practices and the veterinarian's perception level of biosecurity. The biosecurity stages with the lowest application level, therefore representing the biggest threats, were bio-exclusion (increasing the risk of disease introduction) and biocontainment (increasing the risk of inter-herd transmission).
Collapse
Affiliation(s)
- V Renault
- Faculty of Veterinary Medicine, Research Unit in Epidemiology and Risk Analysis Applied to Veterinary Sciences (UREAR-ULg), Fundamental and Applied Research for Animal Health (FARAH) Centre, University of Liege, Liege, Belgium
| | - M F Humblet
- Department of Occupational Safety and Health, Biosafety and Biosecurity Unit, University of Liege, Liege, Belgium
| | - V Moons
- Faculty of Veterinary Medicine, Research Unit in Epidemiology and Risk Analysis Applied to Veterinary Sciences (UREAR-ULg), Fundamental and Applied Research for Animal Health (FARAH) Centre, University of Liege, Liege, Belgium
| | - G Bosquet
- Société Nationale des Groupements Techniques Vétérinaires, Paris, France
| | - B Gauthier
- Veterinary Professional Union, Committee of Rural Practitioners, Nivelles, Belgium
| | - L M Cebrián
- Asociación nacional de especialistas en medicina bovina, Asturias, Spain
| | - J Casal
- Departament de Sanitat I Anatomia Animals, Universitat Autonoma de Barcelona/IRTA-CReSA, Barcelona, Spain
| | - C Saegerman
- Faculty of Veterinary Medicine, Research Unit in Epidemiology and Risk Analysis Applied to Veterinary Sciences (UREAR-ULg), Fundamental and Applied Research for Animal Health (FARAH) Centre, University of Liege, Liege, Belgium
| |
Collapse
|
13
|
|
14
|
Sintayehu G, Melesse B, Abayneh D, Sintayehu A, Melaku S, Alehegne W, Mesfin S, De Blas I, Casal J, Allepuz A, Martin-Valls G, Africa T, Abera K. Epidemiological survey of brucellosis in sheep and goats in selected pastoral and agro-pastoral lowlands of Ethiopia. REV SCI TECH OIE 2016; 34:881-93. [PMID: 27044159 DOI: 10.20506/rst.34.3.2403] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
An epidemiological survey was conducted in pastoral regions of Ethiopia to investigate the distribution of brucellosis in sheep and goats. Between November 2004 and December 2007, a total of 6,201 serum samples were collected from 67 randomly selected peasant associations, 25 districts and eight pastoral zones of Ethiopia. The Rose Bengal plate test (RBPT) and complement fixation test were used in series. Samples for bacteriology were collected from three export abattoirs, where 285 goats were randomly selected and tested by RBPTthree days before slaughter. Tissue samples were collected from 14 strongly positive goats and cultured in dextrose agar and Brucella agar base. To confirm and subtype the isolates, staining, biochemical tests and polymerase chain reaction were used. The overall standardised seroprevalence of brucellosis was 1.9%, ranging from 0.07% in Jijiga zone to 3.3% in Borena zone. There was statistically significant variation among the studied regions, zones, districts and peasant associations (p < 0.05). Male goats and sheep were twice as likely to test positive as females (relative risk [RRJ: 2.04; 95% confidence interval [CI]:1.7-3.4; x2 = 21.05, p < 0.05). Adults (older than 1.5 years) were three times more likely to test positive than younger animals (RR: 2.76; 95% CI: 1.14-6.73; chi2 = 5.18, p < 0.05). Goats were around four times more likely to be infected than sheep (RR: 3.8; 95% CI: 2.4-6.1; chi2 = 36.99, p < 0.05). Brucella melitensis was isolated from 2 of the 14 samples analysed. The widespread distribution of brucellosis in goats and sheep in these areas justifies the use of control measures to minimise the economic losses and public health hazards.
Collapse
|
15
|
Napp S, Allepuz A, Purse BV, Casal J, García-Bocanegra I, Burgin LE, Searle KR. Understanding Spatio-Temporal Variability in the Reproduction Ratio of the Bluetongue (BTV-1) Epidemic in Southern Spain (Andalusia) in 2007 Using Epidemic Trees. PLoS One 2016; 11:e0151151. [PMID: 26963397 PMCID: PMC4786328 DOI: 10.1371/journal.pone.0151151] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Accepted: 02/23/2016] [Indexed: 11/21/2022] Open
Abstract
Andalusia (Southern Spain) is considered one of the main routes of introduction of bluetongue virus (BTV) into Europe, evidenced by a devastating epidemic caused by BTV-1 in 2007. Understanding the pattern and the drivers of BTV-1 spread in Andalusia is critical for effective detection and control of future epidemics. A long-standing metric for quantifying the behaviour of infectious diseases is the case-reproduction ratio (Rt), defined as the average number of secondary cases arising from a single infected case at time t (for t>0). Here we apply a method using epidemic trees to estimate the between-herd case reproduction ratio directly from epidemic data allowing the spatial and temporal variability in transmission to be described. We then relate this variability to predictors describing the hosts, vectors and the environment to better understand why the epidemic spread more quickly in some regions or periods. The Rt value for the BTV-1 epidemic in Andalusia peaked in July at 4.6, at the start of the epidemic, then decreased to 2.2 by August, dropped below 1 by September (0.8), and by October it had decreased to 0.02. BTV spread was the consequence of both local transmission within established disease foci and BTV expansion to distant new areas (i.e. new foci), which resulted in a high variability in BTV transmission, not only among different areas, but particularly through time, which suggests that general control measures applied at broad spatial scales are unlikely to be effective. This high variability through time was probably due to the impact of temperature on BTV transmission, as evidenced by a reduction in the value of Rt by 0.0041 for every unit increase (day) in the extrinsic incubation period (EIP), which is itself directly dependent on temperature. Moreover, within the range of values at which BTV-1 transmission occurred in Andalusia (20.6°C to 29.5°C) there was a positive correlation between temperature and Rt values, although the relationship was not linear, probably as a result of the complex relationship between temperature and the different parameters affecting BTV transmission. Rt values for BTV-1 in Andalusia fell below the threshold of 1 when temperatures dropped below 21°C, a much higher threshold than that reported in other BTV outbreaks, such as the BTV-8 epidemic in Northern Europe. This divergence may be explained by differences in the adaptation to temperature of the main vectors of the BTV-1 epidemic in Andalusia (Culicoides imicola) compared those of the BTV-8 epidemic in Northern Europe (Culicoides obsoletus). Importantly, we found that BTV transmission (Rt value) increased significantly in areas with higher densities of sheep. Our analysis also established that control of BTV-1 in Andalusia was complicated by the simultaneous establishment of several distant foci at the start of the epidemic, which may have been caused by several independent introductions of infected vectors from the North of Africa. We discuss the implications of these findings for BTV surveillance and control in this region of Europe.
Collapse
Affiliation(s)
- S. Napp
- Centre de Recerca en Sanitat Animal (CReSA)—Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Campus UAB, 08193 Bellaterra, Barcelona, Spain
- * E-mail:
| | - A. Allepuz
- Centre de Recerca en Sanitat Animal (CReSA)—Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Campus UAB, 08193 Bellaterra, Barcelona, Spain
- Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Barcelona, Spain
| | - B. V. Purse
- Centre for Ecology and Hydrology, MacLean Bldg, Benson Lane, Crowmarsh Gifford, Wallingford, Oxfordshire, OX10 8BB, United Kingdom
| | - J. Casal
- Centre de Recerca en Sanitat Animal (CReSA)—Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Campus UAB, 08193 Bellaterra, Barcelona, Spain
- Departament de Sanitat i Anatomia Animals, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Barcelona, Spain
| | - I. García-Bocanegra
- Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad de Córdoba (UCO), Campus Universitario de Rabanales, 14071 Córdoba, Spain
| | - L. E. Burgin
- Met Office, FitzRoy Road, Exeter, Devon EX1 3PB United Kingdom
| | - K. R. Searle
- Centre for Ecology and Hydrology, Bush Estate, Penicuik, Midlothian, EH26 0QB, United Kingdom
| |
Collapse
|
16
|
Hemmatian B, Planas E, Casal J. On BLEVE definition, the significance of superheat limit temperature (Tsl) and LNG BLEVE's. J Loss Prev Process Ind 2016. [DOI: 10.1016/j.jlp.2015.12.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Vilar MJ, Peralta B, García-Bocanegra I, Simon-Grifé M, Bensaid A, Casal J, Segalés J, Pina-Pedrero S. Distribution and genetic characterization of Enterovirus G and Sapelovirus A in six Spanish swine herds. Virus Res 2016; 215:42-9. [PMID: 26836019 DOI: 10.1016/j.virusres.2016.01.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2015] [Revised: 01/25/2016] [Accepted: 01/26/2016] [Indexed: 11/18/2022]
Abstract
The prevalence of Enterovirus G (EV-G) and Sapelovirus A (PSV-1) was investigated in Spanish swine herds by means of cross-sectional studies. Faecal samples from clinically healthy pigs were collected from six farms, and analysed by RT-PCR. The results indicated a high prevalence of EV-G detected in nearly all the animals older than 3 weeks of age. Otherwise, PSV-1 was only detected in 3-week-old piglets from one of the farms. Genetic analyses performed in the VP1 region of the EV-G indicated circulation of diverse strains in the same farm, related to genotypes G1, G2, G3, G4, G6, G9, G12, G13 and G14. Moreover, co-infection of several PSV-1 variants in the same animal was evident, typical of viral quasispecies. Evolutionary pressure analysis indicated that microevolution of PSV-1 seems to be driven by negative selection. This study gives further insights in the epidemiology of EV-G and PSV-1.
Collapse
Affiliation(s)
- M J Vilar
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain; Department of Food Hygiene and Environmental Health, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland
| | - B Peralta
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain
| | - I García-Bocanegra
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain; Departamento de Sanidad Animal, Facultad de Veterinaria, UCO, Campus Universitarios de Rabanales, 14071 Córdoba, Spain
| | - M Simon-Grifé
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain
| | - A Bensaid
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain
| | - J Casal
- UAB, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain; Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193, Bellaterra, Barcelona, Spain
| | - J Segalés
- UAB, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain; Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193, Bellaterra, Barcelona, Spain
| | - S Pina-Pedrero
- IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain.
| |
Collapse
|
18
|
Casal J, Rodríguez-Gallardo M, Arias JM. 9Be scattering within a four-body continuum-discretized coupled-channels framework. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611706023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Garcia-Saenz A, Napp S, Lopez S, Casal J, Allepuz A. Estimation of the individual slaughterhouse surveillance sensitivity for bovine tuberculosis in Catalonia (North-Eastern Spain). Prev Vet Med 2015; 121:332-7. [DOI: 10.1016/j.prevetmed.2015.08.008] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 07/29/2015] [Accepted: 08/10/2015] [Indexed: 11/28/2022]
|
20
|
Quintero-Aldana G, Jorge M, Grande C, Salgado M, Gallardo E, Varela S, López C, Villanueva MJ, Fernández A, Alvarez E, González P, Castellanos J, Casal J, López R, Campos Balea B. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer. Cancer Chemother Pharmacol 2015; 76:731-7. [PMID: 26242221 DOI: 10.1007/s00280-015-2839-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Accepted: 07/27/2015] [Indexed: 11/30/2022]
Abstract
PURPOSE Previous studies have shown that docetaxel and cisplatin, as single agents, are effective and relatively well tolerated in patients with advanced gastric cancer. The aim of this study was to assess efficacy and toxicity of a biweekly regimen of docetaxel plus cisplatin in patients with advanced gastric cancer. PATIENTS/METHODS Fifty-five patients with histologically proven advanced gastric cancer with at least 1 measurable lesion and ECOG PS ≤ 2 were enrolled. Patients received docetaxel 50 mg/m(2) and cisplatin 50 mg/m(2) every 2 weeks until progression disease, unbearable toxicity or a maximum of 12 cycles. RESULTS In total, 426 cycles were administered (median 8.5 cycles) to 52 evaluable patients. One patient (1.9 %) showed a complete response, while 21 (40.4 %) had partial responses. The objective response rate was 42.3 % (95 % CI 28.9-55.7), the median time to progression was 5.5 months (95 % CI 4.0-7.0), and the median overall survival was 8.9 months (95 % CI 6.0-11.9). The most common grade 3-4 toxicities per cycle were haematological [neutropenia (5.9 %)]. CONCLUSIONS Biweekly administration of docetaxel and cisplatin in advanced gastric cancer has a manageable toxicity profile and shows a promising antitumour activity as a first-line therapy.
Collapse
Affiliation(s)
| | - M Jorge
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - C Grande
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - M Salgado
- Complejo Hospitalario de Ourense, CHOU, Ourense, Spain
| | - E Gallardo
- Complejo Hospitalario Universitario de Santiago, CHUS, Santiago de Compostela, Spain
| | - S Varela
- Hospital Universitario Lucus, Augusti, Lugo, Spain
| | - C López
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - M J Villanueva
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - A Fernández
- Complejo Hospitalario de Ourense, CHOU, Ourense, Spain.
| | - E Alvarez
- Hospital Universitario Lucus, Augusti, Lugo, Spain
| | - P González
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - J Castellanos
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - J Casal
- Complejo Hospitalario Universitario de Vigo, CHUVI, Vigo, Spain
| | - R López
- Complejo Hospitalario Universitario de Santiago, CHUS, Santiago de Compostela, Spain
| | | |
Collapse
|
21
|
Planas E, Pastor E, Casal J, Bonilla J. Analysis of the boiling liquid expanding vapor explosion (BLEVE) of a liquefied natural gas road tanker: The Zarzalico accident. J Loss Prev Process Ind 2015. [DOI: 10.1016/j.jlp.2015.01.026] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Salvador J, Manso L, de la Haba J, Jaen A, Ciruelos E, de Villena MC, Gil M, Murias A, Galan A, Jara C, Bayo J, Baena JM, Casal J, Mel JR, Blancas I, Sanchez Rvira P. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clin Transl Oncol 2014; 17:160-6. [PMID: 25119930 DOI: 10.1007/s12094-014-1210-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Accepted: 07/21/2014] [Indexed: 11/24/2022]
Abstract
BACKGROUND Efficacy and safety data for combining bevacizumab, gemcitabine, and paclitaxel for locally advanced/metastatic breast cancer are limited. PATIENTS AND METHODS AVALUZ trial evaluates the combination of bevacizumab 10 mg/kg, gemcitabine 2,000 mg/m(2) plus paclitaxel 150 mg/m(2), on days 1 and 15 of each 28-day course in previously untreated HER-2 negative patients. RESULTS Median progression-free survival (PES): 12.3 months. The overall response and clinical benefit rate (CR + PR + SD) were 72 % (95 % CI 60.9-82.0 %) and 89 % (95 % CI 80.3-95.3 %), respectively. Median overall survival: 27.4 mo. Baseline circulating tumor cell (CTCs) ≥2 versus CTCs <2 was associated with lower PFS, p = 0.046. Overall response was significantly greater in patients with intense angiotensin type 1 receptor (AGTR1) expression (99 vs. 60 % [p = 0.021]). The most frequent grade 3/4 adverse events were: neutropenia (10 %); febrile neutropenia (1 %); sensory neuropathy (13 %); and asthenia (6 %). Grade 3 adverse events of interest with bevacizumab included bleeding (1 %) and hypertension (4 %). One patient developed cardiac ischemia (1 %). CONCLUSIONS Adding bevacizumab to chemotherapy appeared feasible and well tolerated, producing toxicity comparable to other effective combined first-line regimens. Baseline circulating endothelial cells and AGTR1 expression are predictive of PFS and response.
Collapse
Affiliation(s)
- J Salvador
- Department of Oncology, Hospital Universitario de Valme, Carretera de Cadiz, KM 548, 28007, Sevilla, Spain,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Guta S, Casal J, Garcia-Saenz A, Saez J, Pacios A, Garcia P, Napp S, Allepuz A. Risk factors for bovine tuberculosis persistence in beef herds of Southern and Central Spain. Prev Vet Med 2014; 115:173-80. [DOI: 10.1016/j.prevetmed.2014.04.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Revised: 03/31/2014] [Accepted: 04/14/2014] [Indexed: 11/25/2022]
|
24
|
|
25
|
Seguí X, Pujolasus E, Betrò S, Agueda A, Casal J, Ocampo-Duque W, Rudolph I, Barra R, Páez M, Barón E, Eljarrat E, Barceló D, Darbra RM. Fuzzy model for risk assessment of persistent organic pollutants in aquatic ecosystems. Environ Pollut 2013; 178:23-32. [PMID: 23524177 DOI: 10.1016/j.envpol.2013.02.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2012] [Revised: 01/29/2013] [Accepted: 02/05/2013] [Indexed: 06/02/2023]
Abstract
We developed a model for evaluating the environmental risk of persistent organic pollutants (POPs) to aquatic organisms. The model is based on fuzzy theory and uses information provided by international experts through a questionnaire. It has been tested in two case studies for a particular type of POPs: brominated flame retardants (BFRs). The first case study is related to the EU-funded AQUATERRA project, with sampling campaigns carried out in two Ebro tributaries in Spain (the Cinca and Vero Rivers). The second one, named the BROMACUA project, assessed different aquatic ecosystems in Chile (San Vicente Bay) and Colombia (Santa Marta Marsh). In both projects, the BFRs under study were polybrominated diphenyl ethers (PBDEs) and hexabromocyclododecane (HBCD). However, the model can be extrapolated to other POPs and to different aquatic ecosystems to provide useful results for decision-makers.
Collapse
Affiliation(s)
- X Seguí
- CERTEC, Dept. of Chemical Engineering, Universitat Politècnica de Catalunya, ETSEIB, Avinguda Diagonal 647, 08028 Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Grande C, Medina M, Martinez M, Willisch P, Huidobro G, Vazquez M, Villanueva M, Muñoz V, Casal J. Flox as adjuvant treatment after chemo-radiotherapy and surgery in rectal cancer. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
27
|
Caeiro M, Huidobro G, Elena H, Willisch P, Martinez M, Leyba R, Triñanes A, Medina M, Fernandez I, Casal J, Muñoz V. Conformed radiotherapy and chemotherapy with cisplatin/tegafur in cervix cancer. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
28
|
Caeiro M, Gomez A, Casal J, Leiva R, Lazaro M, Vazquez S, Pena C, Grande C, Carballo A. Prophylactic cranial irradiation (PCI) in non small cell lung cancer (NSCLC). Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
29
|
Allepuz A, Stevenson M, Kivaria F, Berkvens D, Casal J, Picado A. Risk Factors for Foot-and-Mouth Disease in Tanzania, 2001-2006. Transbound Emerg Dis 2013; 62:127-36. [DOI: 10.1111/tbed.12087] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2012] [Indexed: 11/30/2022]
Affiliation(s)
- A. Allepuz
- Centre de Recerca en Sanitat Animal (CReSA); UAB-IRTA; Campus de la Universitat Autònoma de Barcelona; Barcelona Spain
- Departament de Sanitat i Anatomia Animals; Universitat Autònoma de Barcelona; Barcelona Spain
| | - M. Stevenson
- EpiCentre; Institute of Veterinary, Animal, and Biomedical Sciences; Massey University; Palmerston North New Zealand
| | - F. Kivaria
- National Epidemiology Section; Ministry of Livestock and Fisheries Development; Dar es Salaam Tanzania
| | - D. Berkvens
- Animal Health Department; Institute of Tropical Medicine; Antwerpen Belgium
| | - J. Casal
- Centre de Recerca en Sanitat Animal (CReSA); UAB-IRTA; Campus de la Universitat Autònoma de Barcelona; Barcelona Spain
- Departament de Sanitat i Anatomia Animals; Universitat Autònoma de Barcelona; Barcelona Spain
| | - A. Picado
- School of Life Sciences; University of Warwick; Coventry UK
- Barcelona Centre for International Health Research (CRESIB, Hospital Clínic-Universitat de Barcelona); Barcelona Spain
| |
Collapse
|
30
|
Alba A, Allepuz A, Napp S, Soler M, Selga I, Aranda C, Casal J, Pages N, Hayes EB, Busquets N. Ecological surveillance for West Nile in Catalonia (Spain), learning from a five-year period of follow-up. Zoonoses Public Health 2013; 61:181-91. [PMID: 23590452 DOI: 10.1111/zph.12048] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Indexed: 11/28/2022]
Abstract
To enhance early detection of West Nile virus (WNV) transmission, an integrated ecological surveillance system was implemented in Catalonia (north-eastern Spain) from 2007 to 2011. This system incorporated passive and active equine surveillance, periodical testing of chicken sentinels in wetland areas, serosurveillance wild birds and testing of adult mosquitoes. Samples from 298 equines, 100 sentinel chickens, 1086 wild birds and 39 599 mosquitoes were analysed. During these 5 years, no acute WNV infection was detected in humans or domestic animal populations in Catalonia. WNV was not detected in mosquitoes either. Nevertheless, several seroconversions in resident and migrant wild birds indicate that local WNV or other closely related flaviviruses transmission was occurring among bird populations. These data indicate that bird and mosquito surveillance can detect otherwise silent transmission of flaviviruses and give some insights regarding possible avian hosts and vectors in a European setting.
Collapse
Affiliation(s)
- A Alba
- Centre de Recerca en Sanitat Animal (CReSA), Bellaterra, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Napp S, García-Bocanegra I, Pagès N, Allepuz A, Alba A, Casal J. Assessment of the risk of a bluetongue outbreak in Europe caused by Culicoides midges introduced through intracontinental transport and trade networks. Med Vet Entomol 2013; 27:19-28. [PMID: 23106144 DOI: 10.1111/j.1365-2915.2012.01016.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The importation of infected hosts and the arrival of windborne infected Culicoides (Diptera: Ceratopogonidae) were considered unlikely mechanisms for bluetongue virus (BTV) incursion into a BTV-free area during the recent BTV serotype 8 (BTV-8) epidemic in northern Europe. Therefore, alternative mechanisms need to be considered. Air, sea and land transport networks continue to expand, and an important consequence of this is vector-borne pathogen importation. One important aspect of bluetongue (BT) epidemiology not yet addressed is the potential movement of infected Culicoides via transport and trade networks. Therefore, a risk assessment model was constructed to assess the probability of a BTV outbreak as a consequence of the introduction of Culicoides via these networks. The model was applied to calculate the risk for a BTV-8 epidemic in Spain in 2007 caused by the introduction of Culicoides from affected northern European countries. The mean weighted annual risk for an outbreak caused by transportation of a single vector from an affected northern European country varied from 1.8 × 10(-7) to 3.0 × 10(-13), with the highest risks associated with Culicoides imported from Belgium, the Netherlands, Germany and France. For this mechanism to pose a significant risk to BTV-free countries, a large number of vectors would have to be transported.
Collapse
Affiliation(s)
- S Napp
- Centre de Recerca en Sanitat Animal (CReSA), Universitat Autònoma de Barcelona, Institut de Recerca i Tecnologia Agroalimentáries (UAB-IRTA), Barcelona, Spain.
| | | | | | | | | | | |
Collapse
|
32
|
Firvida J, Vazquez S, Casal J, Alonso M, Varela S, Villanueva M, Afonso F, Fernandez O, Areses C, Campos B. Erlotinib as Frontline Treatment for Elderly Patients (P) with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC): Ggcp044/09 Study. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33794-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
33
|
Allepuz A, Gabriël S, Dorny P, Napp S, Jansen F, Vilar M, Vives L, Picart L, Ortuño A, Gutiérrez J, Casal J. Comparison of bovine cysticercosis prevalence detected by antigen ELISA and visual inspection in the North East of Spain. Res Vet Sci 2012; 92:393-5. [DOI: 10.1016/j.rvsc.2011.03.027] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2010] [Revised: 02/16/2011] [Accepted: 03/10/2011] [Indexed: 11/28/2022]
|
34
|
Fírvida J, Vázquez S, Casal J, Fernández A, Varela S, Villanueva M, Pérez E, Campos B, Salgado M, Mel J. 9088 POSTER Erlotinib as Frontline Treatment for Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and Non-Squamous Histology – Results of a Galician Lung Cancer Group (GGCP044/09 Study) Grupo Galego De Cancro De Pulmon (GGCP). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72400-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
35
|
Vázquez S, Villanueva M, Firvida J, Lázaro M, Campos B, Grande C, Fernandez A, Varela S, Casal J, Perez E. 9085 POSTER Gemcitabine Plus Oral Vinorelbine as Salvage Therapy Treatment for Patients With Advanced Non-small-cell Lung Cancer and Squamous Histology – a Gallclan Lung Cancer Group Study (GGCP042/09) Grupo Galego De Cancro De Pulmon (GGCP). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72397-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
36
|
Grande C, Martinez M, Villanueva M, Huidobro G, Casal J. 6592 POSTER 5-Fluorouracil/Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) as First-Line Treatment of Advanced Gastric Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71903-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
37
|
Salvador J, Jaen A, Ciruelos EM, Codes M, Gil M, Murias A, Galan A, De la Haba JR, Jara C, Bayo JL, Baena JM, Casal J, Mel JR, Blancas I, Gonzalez E, Perez D, Manso L. First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFS analysis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Simon-Grifé M, Martín-Valls G, Vilar M, García-Bocanegra I, Mora M, Martín M, Mateu E, Casal J. Seroprevalence and risk factors of swine influenza in Spain. Vet Microbiol 2011; 149:56-63. [DOI: 10.1016/j.vetmic.2010.10.015] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2010] [Revised: 10/01/2010] [Accepted: 10/22/2010] [Indexed: 10/18/2022]
|
39
|
Salvador J, Jaen A, Ciruelos E, Codes de Villena M, Gil M, Murias A, Galan A, de la Haba J, Jara C, Bayo J, Baena JM, Casal J, Mel JR, Blancas I, Gonzalez E, Perez D, Manso L. Abstract P2-16-13: Phase II Open Label Trial Bevacizumab in Combination with Paclitaxel and Gemcitabine as First Line in Patients with HER-2 Negative Recurrent or Metastatic Breast Cancer (AVALUZ): First Analysis. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-16-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
The combination of bevacizumab with taxanes, capecitabine or anthracyclines has shown increased progression-free survival in patients with metastatic breast carcinoma. The aim of this study is to evaluate the efficacy and toxicity profile of the combination of bevacizumab with gemcitabine and paclitaxel, providing a preliminary analysis of response in patients included for whom at least one response assessment and the toxicity experienced in all patients treated.
Methods:
A Phase II multicenter, national, open-label study in patients diagnosed of recurrent or metastatic HER-2 negative breast carcinoma, treated with first-line bevacizumab 10 mg/kg, paclitaxel 150 mg/m2 and gemcitabine 2000 mg/m2 day 1 and 15 c/28d until disease progression, unacceptable toxicity, or medical decision. This abstract evaluates efficacy by the response rate and the toxicity profile of the combination in all cycles of all patients included. The primary end-point of the study is PFS. Toxicity is evaluated according to NCI CTC v 3.0 criteria. Results:
From January 2009 to December 2009, 82 evaluable patients were recruited in 23 sites, with at least one response assessment available in 69. Median age 51.5 (26-81), ER+ 59 pts, PR+ 51 pts, triple negative patients 16 and previous chemotherapy (neoadj or adj) 58 pts. Of the 69 pts with response assessment, the last assessment is in cycle 3 for 31.88% of patients, cycle 6: 33.33%, cycle 9: 4.35%, cycle 12: 1.45% and at the end of treatment 29%. The median cycles administered per patient is 6 (1-14) and the relative median dose intensity is 0.93 for bevacizumab, 0.91 for paclitaxel, and 0.93 for gemcitabine.
The overall response obtained was 69.57%, with a clinical benefit of 89.86% (CR 8.7% (6), PR 60.87% (42), SD 20.29%, and DP 10.14%). Of the 82 patients with a median follow-up of 7.19 m (0.16-13.98), grade 3-4 toxicity affected 41%, with treatment discontinuation for adverse events in 19.51%. Eighteen SAEs were reported: pyrexia (4), infection at catheter site (2), urine infection and a single case of angor, hypertension, pulmonary embolism, pleural effusion, febrile neutropenia, neutropenia, vomiting, diarrhoea, dehydration, atrial fibrillation, and dizziness. Toxicity was generally easily controlled. Conclusions:
Although data from the primary study endpoint (PFS) are not yet available, the treatment regimen obtained a high overall response in patients treated and was well tolerated by this patient group.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-16-13.
Collapse
Affiliation(s)
- J Salvador
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - A Jaen
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - E Ciruelos
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - M Codes de Villena
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - M Gil
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - A Murias
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - A Galan
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - J de la Haba
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - C Jara
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - J Bayo
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - JM Baena
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - J Casal
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - JR Mel
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - I Blancas
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - E Gonzalez
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - D Perez
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| | - L. Manso
- Hospital U. Valme, Sevilla, Spain; Hospital de Jaen, Jaen, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; ICO, Bellvitge, Spain; Hospital Insular de Gran Canaria, Las Palmas, Spain; Hospital de Sagunto, Sagunto, Spain; Hospital Reina Sofia, Cordoba, Spain; Hospital F. Alcorcón, Alcorcón, Spain; Hospital Juan Ramón Jimenez, Huelva, Spain; Hospital Puerta del Mar, Cadiz, Spain; Hospital Meixoeiro, Vigo, Spain; Hospital Xeral Calde, Lugo, Spain; Hospital San Cecilio, Granada, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Costa del Sol, Marbella, Spain
| |
Collapse
|
40
|
Allepuz A, García-Bocanegra I, Napp S, Casal J, Arenas A, Saez M, González MA. Monitoring bluetongue disease (BTV-1) epidemic in southern Spain during 2007. Prev Vet Med 2010; 96:263-71. [PMID: 20663576 DOI: 10.1016/j.prevetmed.2010.06.005] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2009] [Revised: 06/09/2010] [Accepted: 06/10/2010] [Indexed: 10/19/2022]
Abstract
On the 25th of July 2007, bluetongue virus (BTV) serotype 1 was detected in Andalusia, southern Spain for the first time. A total of 4436 farms infected with BTV-1 were confirmed during that year: 3162 in sheep flocks, 113 in goat flocks, 7 in cattle herds and 1154 in mixed farms (sheep, goat and/or cattle in the same farm). The most common clinical signs were: fever, depression, lethargy, facial edema, and salivation (observed in more than 70% of the infected farms). Lesions in oral mucosa, lameness and dyspnea were also frequently observed. Median morbidity rate in sheep and goat flocks were 6.3% and 2.7% respectively. Median mortality rate was 2.2% in sheep flocks and 1.2% in goat flocks. Median case fatality rate was 29.8% in sheep flocks and 45% in goat flocks. Morbidity and mortality rates were not significantly higher in sheep flocks than in goat flocks (p>0.05), whereas case fatality rate was significant higher in goat flocks compared to sheep flocks (p<0.05). Neither clinical signs nor mortality were observed in cattle herds. The spatial distribution of the risk of BTV infection over Andalusia by municipality was evaluated by means of a hierarchical Bayesian model. The results evidenced that the risk was not homogeneous over the territory, being higher in the western part of the region. The likelihood of BTV infection was increased between 1.01 and 1.16 times by an increase of 10,000 domestic ruminants, and between 1.01 and 1.69 times by the presence of red deer (Cervus elaphus) in the municipality.
Collapse
Affiliation(s)
- A Allepuz
- Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
| | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
Foot-and-mouth disease (FMD) is endemic in Tanzania, with outbreaks occurring almost each year in different parts of the country. There is now a strong political desire to control animal diseases as part of national poverty alleviation strategies. However, FMD control requires improving the current knowledge on the disease dynamics and factors related to FMD occurrence so control measures can be implemented more efficiently. The objectives of this study were to describe the FMD dynamics in Tanzania from 2001 to 2006 and investigate the spatiotemporal patterns of transmission. Extraction maps, the space-time K-function and space-time permutation models based on scan statistics were calculated for each year to evaluate the spatial distribution, the spatiotemporal interaction and the spatiotemporal clustering of FMD-affected villages. From 2001 to 2006, 878 FMD outbreaks were reported in 605 different villages of 5815 populated places included in the database. The spatial distribution of FMD outbreaks was concentrated along the Tanzania-Kenya, Tanzania-Zambia borders, and the Kagera basin bordering Uganda, Rwanda and Tanzania. The spatiotemporal interaction among FMD-affected villages was statistically significant (P≤0.01) and 12 local spatiotemporal clusters were detected; however, the extent and intensity varied across the study period. Dividing the country in zones according to their epidemiological status will allow improving the control of FMD and delimiting potential FMD-free areas.
Collapse
Affiliation(s)
- A Picado
- Department of Animal Health, Institute of Tropical Medicine, Antwerp, Belgium.
| | | | | | | | | | | | | |
Collapse
|
42
|
Alba A, Casal J, Napp S, Martin PAJ. Assessment of different surveillance systems for avian influenza in commercial poultry in Catalonia (North-Eastern Spain). Prev Vet Med 2010; 97:107-18. [PMID: 20943281 DOI: 10.1016/j.prevetmed.2010.09.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2009] [Revised: 08/17/2010] [Accepted: 09/01/2010] [Indexed: 10/19/2022]
Abstract
Compulsory surveillance programmes for avian influenza (AI) have been implemented in domestic poultry and wild birds in all the European Member States since 2005. The implementation of these programmes is complex and requires a close evaluation. A good indicator to assess their efficacy is the sensitivity (Se) of the surveillance system. In this study, the sensitivities for different sampling designs proposed by the Spanish authorities for the commercial poultry population of Catalonia were assessed, using the scenario tree model methodology. These samplings were stratified throughout the territory of Spain and took into account the species, the types of production and their specific risks. The probabilities of detecting infection at different prevalences at both individual and holding level were estimated. Furthermore, those subpopulations that contributed more to the Se of the system were identified. The model estimated that all the designs met the requirements of the European Commission. The probability of detecting AI circulating in Catalonian poultry did not change significantly when the within-holding design prevalence varied from 30% to 10%. In contrast, when the among-holding design prevalence decreased from 5% to 1%, the probability of detecting AI was drastically reduced. The sampling of duck and goose holdings, and to a lesser extent the sampling of turkey and game bird holdings, increased the Se substantially. The Se of passive surveillance in chickens for highly pathogenic avian influenza (HPAI) and low pathogenicity avian influenza (LPAI) were also assessed. The probability of the infected birds manifesting apparent clinical signs and the awareness of veterinarians and farmers had great influence on the probability of detecting AI. In order to increase the probability of an early detection of HPAI in chicken, the probability of performing AI specific tests when AI is suspected would need to be increased.
Collapse
Affiliation(s)
- A Alba
- Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Campus de la Universitat Autònoma de Barcelona. 08193 Bellaterra, Barcelona, Spain.
| | | | | | | |
Collapse
|
43
|
García-Bocanegra I, Dubey J, Simon-Grifé M, Cabezón O, Casal J, Allepuz A, Napp S, Almería S. Seroprevalence and risk factors associated with Toxoplasma gondii infection in pig farms from Catalonia, north-eastern Spain. Res Vet Sci 2010; 89:85-7. [DOI: 10.1016/j.rvsc.2010.01.017] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2009] [Revised: 12/17/2009] [Accepted: 01/29/2010] [Indexed: 11/25/2022]
|
44
|
Casal J, Varela S, Anido U, Lázaro M, Fírvida JL, Vazquez-Estevez S, Villanueva M, Amenedo M, Caeiro M, Gomez A. Docetaxel (D) and cisplatin (C) induction chemotherapy followed by concurrent thoracic radiotherapy (TRT) and biweekly D and C for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Vazquez S, Firvida J, Lázaro M, Barón FJ, Alonso-Jaudenes Curbera G, Amenedo M, Santomé L, Afonso FJ, Cardona JV, Casal J. A Galician Lung Cancer Group phase II study: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7091] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Leon L, Vazquez S, Gracia J, Casal J, Lázaro M, Fírvida JL, Amenedo M, Santomé L, Cardona JV, Maciá S. A Galician Lung Cancer Group phase II study of bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
López-Soria S, Maldonado J, Riera P, Nofrarías M, Espinal A, Valero O, Blanchard P, Jestin A, Casal J, Domingo M, Artigas C, Segalés J. Selected Swine Viral Pathogens in Indoor Pigs in Spain. Seroprevalence and Farm-Level Characteristics. Transbound Emerg Dis 2010; 57:171-9. [DOI: 10.1111/j.1865-1682.2010.01135.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
48
|
Allepuz A, Saez M, Solymosi N, Napp S, Casal J. The role of spatial factors in the success of an Aujeszky's disease eradication programme in a high pig density area (Northeast Spain, 2003–2007). Prev Vet Med 2009; 91:153-60. [DOI: 10.1016/j.prevetmed.2009.06.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2008] [Revised: 06/05/2009] [Accepted: 06/10/2009] [Indexed: 11/24/2022]
|
49
|
Vazquez S, Leon L, Gracia J, Casal J, Lazaro M, Firvida J, Amenedo M, Santome L, Cardona J, Macia S. 9145 Bevacizumab (B), cisplatin and vinorelbine in chemo-naïve patients (P) with non squamous non small cell lung cancer (NSCLC): a galician lung cancer group phase II study. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71858-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
50
|
Leon L, Vázquez S, Gracia JM, Lázaro M, Fírvida JL, Casal J, Amenedo M, Santomé L, Gallego R, Anido U. Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19089 Background: Bevacizumab, an anti-VEGF monoclonal antibody, improves response rates and prolongs survival in p with non squamous NSCLC when combined with carboplatin-paclitaxel or cisplatin-gemcitabine. This single-arm, open-labeled phase II trial aims to evaluate the efficacy and safety profile of B in combination with another widely used chemotherapy doublet for NSCLC: cisplatin and vinorelbine. Methods: Chemotherapy-naïve p diagnosed with stage IIIB or IV non squamous NSCLC received cisplatin (80 mg/m2), vinorelbine (25 mg/m2 IV days 1 and 8) and B (15 mg/kg IV) on day 1 every 3 weeks for up to 6 cycles followed by B 15 mg/kg alone every 3 weeks until disease progression. Main eligibility criteria were: PS 0–1, no brain metastases, no history of hemoptysis, stable cardiac condition and no full dose anticoagulation. Primary endpoint was progression-free survival and secondary endpoints were RR, duration of response, OS, 1-year survival and safety profile of the combination. Results: 38 p have been enrolled in the study and data of 27 p have been included in this analysis. P characteristics were: male 66.7%; median age 57 years (range 41–74); ECOG PS 0/1 (%) 33.3/66.7; adenocarcinoma/other (%) 74.1/25.9; stage IIIB/IV (%) 25.9/74.1. Median number of cycles for B/cisplatin/vinorelbine was 4.0 (range 1–6) and median number of cycles for B maintenance was 2 (range 1–4). 17 p were evaluable for response according to RECIST criteria: PR 29.4% and SD 41.2%. With a median follow-up of 3.9 months (range 0.7–11.1), median PFS was 4.6 months (95% CI: 2.6–6.6) and median OS has not been reached yet. Hematological toxicities were: 1 p gr. 3 anemia; 2 p gr. 3 and 2 p gr. 4 leucopenia; 10 p gr. 3, 1 p gr. 4 neutropenia and 3 p febrile neutropenia. Most common grade 3/4 non hematological toxicities were: vomiting (1p gr. 4), high blood pressure, asthenia and hyperglycemia. 1 p experienced gr. 4 abdominal pain, 1 p. gr. 4 constipation, 1 p. gr. 4 nausea and 1 p gr. 4 respiratory infection. No grade 3/4 hemoptysis were reported. Conclusions: This interim analysis shows that B in combination with cisplatin and vinorelbine is safe and well tolerated and has a promising activity in chemo-naïve p with non squamous NSCLC. Survival data will be updated. [Table: see text]
Collapse
Affiliation(s)
- L. Leon
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - S. Vázquez
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. M. Gracia
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - M. Lázaro
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. L. Fírvida
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. Casal
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - M. Amenedo
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - L. Santomé
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - R. Gallego
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - U. Anido
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| |
Collapse
|